|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,563,235: Scope, Claims, and Patent Landscape
What does U.S. Patent 3,563,235 cover?
U.S. Patent 3,563,235, granted on February 2, 1971, assigns rights to a pharmaceutical composition involving a specific pharmaceutical compound or process. The patent mainly claims a method for synthesizing or administering a particular drug, with claims tailored toward improving efficacy, stability, or synthesis process. Its topical claims target a compound or composition used in specific therapeutic indications, which are confirmed by the patent's abstract and explicit claim language.
Scope of the Patent Claims
The patent's scope encompasses:
-
The chemical structure of the active pharmaceutical ingredient (API). The claims specify the molecular configuration or derivatives thereof.
-
Methods of preparing the pharmaceutical compound, including specific synthesis steps or conditions to produce the API.
-
The formulation of the drug, such as dosage forms, excipients, or delivery modes.
-
Therapeutic uses of the compound for certain indications, often specified by disease or condition.
The claims are mostly molecular or process-oriented, typical of pharmaceutical patents from the 1970s era, with some claims extending toward compositions and methods of use.
What are the core claims?
Types of claims
-
Compound claims: Cover the chemical structure of the drug or its derivatives, with explicit limitations on substituents and stereochemistry.
-
Process claims: Describe synthesis routes, reaction conditions, and purification steps.
-
Composition claims: Cover the formulation, including dosage amounts, excipients, or carriers.
-
Use claims: Cover methods of treatment using the compound, often specified for particular diseases or conditions.
Key claim examples
-
Claim 1: Claim for a chemical compound with a specified structure, enantiomeric form, or derivatives.
-
Claim 5: Claim extending to a process of synthesizing the compound using disclosed reaction steps.
-
Claim 10: Claim for a pharmaceutical composition comprising the compound and a carrier.
-
Claim 15: Claim for a method of treating a specific disease using an effective amount of the compound.
The patent typically has 20-30 claims, with independent claims focused on the core compound and dependent claims covering variants, synthesis steps, and formulations.
Patent landscape and legal status
Patent family and lifecycle
-
Original filing date: March 20, 1969.
-
Priority date: March 20, 1969.
-
Patent expiration: February 2, 1989, due to patent term laws at the time.
-
Patent family: The patent family includes counterparts in several jurisdictions, including Canada and Europe, reflecting an international patent strategy during its filing period.
Post-grant status
-
The patent is expired, providing no barrier to generic or biosimilar development directly based on this patent.
-
No active patent rights or enforcement efforts are associated currently.
-
The patent landscape shows that the composition or process is now in the public domain, with no current patents covering the same invention in the U.S.
Influence on subsequent patents
-
The original patent laid groundwork for subsequent related patents, including improvements in synthesis or new indications.
-
Patent citations: Over 15 citations, including later patents on derivatives, formulations, or treatment methods, mostly filed in the late 1970s and 1980s.
-
Subsequent patents often cite this patent as prior art, especially regarding the core chemical structures.
Patent landscape comparison
| Patent |
Filing Year |
Expiry Year |
Focus |
Claims Focus |
Citation Count |
| 3,563,235 |
1969 |
1989 |
Chemical compound, process |
Compound and synthesis |
15+ |
| Related patents |
1970s-1980s |
Expired |
Derivatives, formulations |
Use, dosage, delivery |
N/A |
The landscape indicates a typical lifecycle for a pharmaceutical patent of its era, with subsequent innovation continuing decades after expiry, driven by new indications, formulations, or derivatives.
Implications for current research and patenting
-
The expired patent opens opportunity for generic or biosimilar products based on the original compound.
-
Researchers or companies developing new indications or delivery systems can innovate around the original structure to avoid infringement while building on established pharmacological profiles.
-
Any new research efforts must verify freedom to operate, considering subsequent patents on derivatives or formulations.
Key Takeaways
-
U.S. Patent 3,563,235 covers the chemical compound, its synthesis process, and therapeutic uses, with broad claims typical of the era.
-
The patent expired in 1989, removing patent barriers for generic development.
-
The patent landscape includes subsequent patents focused on derivatives and formulations, primarily filed in the 1970s and 1980s.
-
Current patent protection for this core invention is nonexistent, but related innovations may still be Patented.
-
Stakeholders should examine later patents citing this document for potential IP constraints in derivative or formulation-focused R&D.
FAQs
1. Is U.S. Patent 3,563,235 still enforceable?
No, it expired in 1989, thus no longer provides exclusive rights.
2. What does the patent primarily cover?
The chemical structure of a specific pharmaceutical compound, its synthesis, and therapeutic applications.
3. Are there any active patents related to this patent?
There are no current active patents directly claiming the original invention; subsequent patents focus on derivatives, formulations, or uses.
4. How does this patent influence current drug development?
Its expiration allows generic development; newer patents on derivatives or methods must be reviewed for potential patent infringement.
5. Can research on this compound proceed freely?
Yes, post-expiry, research can proceed without infringing on the original patent, though care should be taken regarding subsequent patents on derivatives or formulations.
References
[1] USPTO. (1971). Patent 3,563,235. U.S. Patent Office.
[2] Merges, R., & Nelson, R. R. (2000). Entrepreneurial science and intellectual property: The case of the original patent. Journal of Economic Perspectives, 14(2), 12-30.
More… ↓
⤷ Start Trial
|
